2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD2

CD2

Cluster of differentiation 2

CD2 is a transmembrane glycoprotein primarily expressed on the surface of T cells, natural killer (NK) cells, and thymocytes, belonging to the immunoglobulin superfamily. It binds to LFA-3 on the cell surface and plays an important role in immune responses, especially in the formation and organization of the immunological synapse. CD2 enhances T cell activation by binding to LFA-3, thereby boosting immune responses. The expression of CD2 is upregulated on memory T cells and activated T cells, playing a crucial role in the activation of memory T cells.
CD2 also plays a significant role in regulating immune cell functions, particularly in organ transplantation and certain autoimmune diseases. By inhibiting the CD2/LFA-3 co-stimulatory pathway, CD2 can reduce the excessive activation of T cells and NK cells, thereby lowering the risk of graft rejection and prolonging graft survival. Additionally, research indicates that CD2 plays a critical role in NK cell spontaneous cytotoxicity and certain cancer immune responses. Therefore, CD2 presents a broad application potential as an immune-regulatory target, especially in the study of autoimmune diseases and promoting immune tolerance in organ transplantation.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99904
    Siplizumab
    		Inhibitor 99.83%
    Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells.
    Siplizumab
  • HY-P99757
    Nivatrotamab
    		Inhibitor 99.40%
    Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma.
    Nivatrotamab
  • HY-158109
    M3554
    		Inhibitor 99.39%
    M3554 is an anti-GD2 antibody-drug conjugate (ADC) based on the humanized anti-GD2 antibody. M3554 consists of the humanized monoclonal antibody Dinutuximab (HY-P9933) linked to a topoisomerase 1 inhibitor Exatecan (HY-13631) via a cleavable β-glucuronide linker. M3554 can be used for the study of neuroblastoma, osteosarcoma or glioma.
    M3554
  • HY-P991543
    BTI-322
    		Inhibitor
    BTI-322 is a rat monoclonal IgG2b directed against the CD2 antigen on T cells and NK cells. BTI-322 can block primary and memory alloantigen proliferative responses in vitro. BTI-322 recognizes over 90% of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias. BTI-322 has immunosuppressive activity. BTI-322 effectively inhibits T cell responses in vitro to allogeneic cells. BTI-322 can be used as a T-cell deplting agent. BTI-322 can be studied in research for renal allograft rejection and steroid-refractory acute graft-versus-host disease.
    BTI-322
  • HY-P990286
    Anti-Rat CD2 Antibody (OX-34)
    Anti-Rat CD2 Antibody (OX-34) is mouse-derived IgG2a κ type antibody inhibitor, targeting to rat CD2. Anti-Rat CD2 Antibody (OX-34) can block CD2 and inhibit the mixed lymphocyte reaction. Anti-Rat CD2 Antibody (OX-34) can be used for the researches of cancer, inflammation and immunology, such as RNK-16 tumor and arthritis.
    Anti-Rat CD2 Antibody (OX-34)
  • HY-P990868
    Anti-CD2 Antibody (CB.219)
    		Inhibitor
    Anti-CD2 Antibody (CB.219) is an anti-human CD2 IgG2b monoclonal antibody. Anti-CD2 Antibody (CB.219) can reduce the infiltration of T cells, macrophages, and the number of Tregs in the colon. Anti-CD2 Antibody (CB.219) can be used for research on infection and inflammation such as toxoplasma infection and colitis. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982).
    Anti-CD2 Antibody (CB.219)
Cat. No. Product Name / Synonyms Application Reactivity